DK2820010T3 - Benzofuran-2-sulfonamid-derivativer som kemokinreceptormodulatorer - Google Patents

Benzofuran-2-sulfonamid-derivativer som kemokinreceptormodulatorer Download PDF

Info

Publication number
DK2820010T3
DK2820010T3 DK13711995.4T DK13711995T DK2820010T3 DK 2820010 T3 DK2820010 T3 DK 2820010T3 DK 13711995 T DK13711995 T DK 13711995T DK 2820010 T3 DK2820010 T3 DK 2820010T3
Authority
DK
Denmark
Prior art keywords
mmol
retinal
compound
etoac
nmr
Prior art date
Application number
DK13711995.4T
Other languages
English (en)
Inventor
Haiqing Yuan
Richard L Beard
Xiaoxia Liu
John E Donello
Veena Viswanath
Michael E Garst
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK2820010T3 publication Critical patent/DK2820010T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (5)

  1. 1. Forbindelse med følgende formel, hydraterne, solvaterne, krystalformerne, tautomererne eller et farmaceutisk acceptabelt salt deraf:
  2. 2. Farmaceutisk sammensætning, der som aktiv bestanddel omfatter en terapeutisk effektiv mængde af en forbindelse ifølge krav 1 og en farmaceutisk acceptabel adjuvans, diluenter eller bærer.
  3. 3. Farmaceutisk sammensætning ifølge krav 2 til anvendelse i en fremgangsmåde til behandling afen lidelse, der er forbundet med kemokinreceptormodulering, hvilken fremgangsmåde omfatter administration af den farmaceutiske sammensætning til et pattedyr, som har behov derfor, hvor den lidelse, der er forbundet med kemokinreceptormodulering, er valgt blandt inflammatoriske hudsygdomme og -tilstande og inflammatoriske øjensygdomme.
  4. 4. Farmaceutisk sammensætning til anvendelse ifølge krav 3, hvor de inflammatoriske hudsygdomme og -tilstande er valgt blandt rosacea, solskoldning, kronisk solskade, diskrete erytemer, psoriasis, atopisk dermatitis, menopauseforbundne hedeture, hedeture som følge af orkiektomi, fotoaldring, seboroisk dermatitis, akne, allergisk dermatitis, irriterende dermatitis, telangiektasi i ansigtet, rinofym, rød løgformet næse, aknelignende huderuptioner, brændende eller svidende fornemmelse i ansigtet, irriterede og blodskudte og vandige øjne, kutan hyperaktivitet med udvidelse af hudens blodkar, Lyells syndrom, Stevens-Johnson-syndrom, erythema multiforme minor, erythema multiforme major og andre inflammatoriske hudsygdomme, aktiniske keratoser, arsenikkeratoser, inflammatorisk og ikke-inflammatorisk akne, iktyoser og andre keratiniseringslidelser og hyperproliferative lidelser i huden, eksem, sårheling; og hvor de inflammatoriske øjensygdomme er valgt blandt uveitis, tørt øje, keratitis, allergisk øjensygdom og -tilstande, der påvirker den bageste del af øjet, valgfrit valgt blandt makulopatier og retinal degeneration, herunder ikke-eksudativ aldersrelateret makulær degeneration, eksudativ aldersrelateret makulær degeneration, koroidal neovaskularisering, diabetisk retinopati, akut makulær neuroretinopati, central serøs korioretinopati, cystoid makulær ødem og diabetisk makulær ødem; uveitis, retinitis og koroiditis, valgfrit valgt blandt akut multifokal placoid pigmentepiteliopati, Behcets sygdom, "birdshot"-retinokoroidopati, infektiøs (syfilis, lyme, tuberkulose, toksoplasmose) intermediær uveitis, multifokal koroiditis, multipelt forbigående hvid plet-syndrom, okulær sarkoidose, posterior scleritis, serpiginøs koroiditis, subretinal fibrose og uveitissyndrom, Vogt-Koyanagi-Harada-syndrom; vaskulære sygdomme/eksudative sygdomme, valgfrit valgt blandt retinal arteriel okklusiv sygdom, central retinal veneokklusion, dissemineret intravaskulær koagulopati, retinal grenveneokklusion, hypertensive fundus-ændringer, okulær iskæmisk syndrom, retinale arterielle mikroaneurysmer, Coats sygdom, parafoveal telangiektase, hemiretinal veneokklusion, papillophlebitis, central retinal arterieokklusion, retinal grenarterieokklusion, karotidarteriesygdom, matteret gren-angiitis ("frosted branch angiitis"), seglcelleretinopati og andre hæmoglobinopatier, angioide striber, familiær eksudativ vitreoretinopati og Eales sygdom; traumatiske/kirurgiske tilstande, valgfrit valgt blandt sympatisk oftalmi, retinal uveitissygdom, retinal løsrivelse, traume, tilstande forårsaget af laser, tilstande forårsaget af fotodynamisk terapi, fotokoagulation, hypoperfusion under kirurgi, strålingsretinopati og knoglemarvstransplantationsretinopati; proliferative lidelser, valgfrit valgt blandt proliferativ vitreal retinopati og epiretinale membraner og proliferativ diabetisk retinopati; infektiøse lidelser, valgfrit valgt blandt okulær histoplasmose, okulær toksokariase, formodet okulær histoplasmosesyndrom, endophthalmitis, toksoplasmose, retinale sygdomme, som er forbundet med HIV-infektion, koroidal sygdom, som er forbundet med HIV-infektion, uveitissygdom, som er forbundet med HIV-infektion, viral retinitis, akut retinalnekrose, progressiv ydre retinalnekrose, retinale svampesygdomme, okulær syfilis, okulær tuberkulose, diffus unilateral subakut neuroretinitis og myiase; genetiske lidelser, valgfrit valgt blandt retinitis pigmentosa, systemiske lidelser med forbundne retinale dystrofier, kongenital stationær natteblindhed, tapdystrofier, Stargardts sygdom og fundus flavimaculatus, Bests' sygdom, mønsterdystrofi i det retinale pigmenterede epitel, X-bundet retinoskise, Sorsbys fundus-dystrofi, benign koncentrisk makulopati, Biettis krystallinsk dystrofi og pseudoxanthoma elasticum; retinale tårer/huller, valgfrit valgt blandt retinal løsrivelse, makulært hul og retinal gianttåre ("giant retinal tear"); tumorer, valgfrit valgt blandt retinal sygdom, som er forbundet med tumorer, kongenital hypertrofi i det retinale pigmenterede epitel, posterior uveal melanom, koroidal hæmangiom, koroidal osteom, koroidal metastase, kombineret hamartom i retina og retinal pigmenteret epitel, retinoblastom, vasoproliferative tumorer i den okulære fundus, retinal astrocytom og intraokulære lymfoide tumorer; og forskellige andre sygdomme, der påvirker den bageste del af øjet, valgfrit valgt blandt punktformig indre koroidopati, akut posterior multifokal placoid pigmentepiteliopati, myopisk retinal degeneration og akut retinal pigmentepiteliitis.
  5. 5. Farmaceutisk sammensætning til anvendelse ifølge krav 3 eller krav 4, hvor pattedyret er et menneske.
DK13711995.4T 2012-03-01 2013-03-01 Benzofuran-2-sulfonamid-derivativer som kemokinreceptormodulatorer DK2820010T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605300P 2012-03-01 2012-03-01
PCT/US2013/028607 WO2013130962A1 (en) 2012-03-01 2013-03-01 Benzofuran- 2 - sulfonamide derivatives as chemokine receptor modulators

Publications (1)

Publication Number Publication Date
DK2820010T3 true DK2820010T3 (da) 2018-08-06

Family

ID=47902352

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13711995.4T DK2820010T3 (da) 2012-03-01 2013-03-01 Benzofuran-2-sulfonamid-derivativer som kemokinreceptormodulatorer
DK18156011.1T DK3345899T3 (da) 2012-03-01 2013-03-01 Benzofuran-2-sulfonamidderivater som kemokinreceptormodulatorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18156011.1T DK3345899T3 (da) 2012-03-01 2013-03-01 Benzofuran-2-sulfonamidderivater som kemokinreceptormodulatorer

Country Status (12)

Country Link
US (4) US8815915B2 (da)
EP (2) EP2820010B1 (da)
AU (2) AU2013225815B2 (da)
CA (1) CA2866078C (da)
CY (1) CY1120528T1 (da)
DK (2) DK2820010T3 (da)
ES (2) ES2791534T3 (da)
HU (2) HUE038700T2 (da)
PL (2) PL3345899T3 (da)
PT (2) PT2820010T (da)
SI (1) SI2820010T1 (da)
WO (2) WO2013130962A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2820010B1 (en) * 2012-03-01 2018-05-09 Allergan, Inc. Benzofuran-2-sulfonamide derivatives as chemokine receptor modulators
WO2014159657A1 (en) * 2013-03-12 2014-10-02 Allergan, Inc. Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators
WO2015084869A1 (en) * 2013-12-02 2015-06-11 Allergan, Inc. Benzothiophene sulfonamides derivatives as chemokine receptor modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US20070021466A1 (en) * 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7393873B2 (en) 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
NZ545030A (en) * 2003-08-08 2009-08-28 Janssen Pharmaceutica Nv 2-(Quinoxalin-5-ylsulfonylamino) -benzamide compounds as CCK2 modulators
US7622583B2 (en) * 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
GB0524786D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
US20100234364A1 (en) 2006-07-14 2010-09-16 Arindrajit Basak Ccr2 inhibitors and methods of use thereof
MX2009000395A (es) * 2006-07-14 2009-01-29 Chemocentryx Inc Triazolil fenil bencenosulfonamidas.
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
CA2692761C (en) 2007-07-12 2013-04-30 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
TWI440638B (zh) * 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物
EP2651957B1 (en) * 2010-12-16 2015-02-18 Allergan, Inc. Phosphorous derivatives as chemokine receptor modulators
EP2955173B1 (en) * 2010-12-16 2017-10-04 Allergan, Inc. 1,2-bis-sulfonamide derivatives as chemokine receptor modulators
CA2859024C (en) * 2011-12-12 2016-11-08 Allergan, Inc. Benzisothiazol-3(1h)-one-5-sulfonyl derivatives as chemokine receptor modulators
EP2820010B1 (en) * 2012-03-01 2018-05-09 Allergan, Inc. Benzofuran-2-sulfonamide derivatives as chemokine receptor modulators
WO2014159657A1 (en) * 2013-03-12 2014-10-02 Allergan, Inc. Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators

Also Published As

Publication number Publication date
US9550746B2 (en) 2017-01-24
US20150218119A1 (en) 2015-08-06
US8815915B2 (en) 2014-08-26
AU2018200226A1 (en) 2018-01-25
US20130231339A1 (en) 2013-09-05
AU2018200226B2 (en) 2019-09-19
US20130231338A1 (en) 2013-09-05
PL2820010T3 (pl) 2018-11-30
EP3345899B1 (en) 2020-02-19
EP3345899A1 (en) 2018-07-11
AU2013225815A1 (en) 2014-09-25
ES2791534T3 (es) 2020-11-04
PL3345899T3 (pl) 2020-07-27
ES2683046T3 (es) 2018-09-24
EP2820010A1 (en) 2015-01-07
CA2866078A1 (en) 2013-09-06
US8927544B2 (en) 2015-01-06
CA2866078C (en) 2018-01-02
CY1120528T1 (el) 2019-07-10
DK3345899T3 (da) 2020-05-11
US20140329813A1 (en) 2014-11-06
AU2013225815B2 (en) 2017-10-12
PT3345899T (pt) 2020-05-20
HUE038700T2 (hu) 2018-11-28
WO2013130962A1 (en) 2013-09-06
WO2013130958A1 (en) 2013-09-06
PT2820010T (pt) 2018-10-01
SI2820010T1 (sl) 2018-11-30
HUE049728T2 (hu) 2020-10-28
US9416120B2 (en) 2016-08-16
EP2820010B1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
EP2651957B1 (en) Phosphorous derivatives as chemokine receptor modulators
AU2018200226B2 (en) Benzofuran-2-sulfonamide derivatives as chemokine receptor modulators
CA2859024C (en) Benzisothiazol-3(1h)-one-5-sulfonyl derivatives as chemokine receptor modulators
EP2970239B1 (en) Sulfonamide derivatives as chemokine receptor modulators
WO2015084869A1 (en) Benzothiophene sulfonamides derivatives as chemokine receptor modulators